Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Pulse Biosciences, Inc. reported revenue of $0M. Operating margin was -21982.6% and net margin -20794.6%, on a free-cash-flow margin of -15553.4% with capital expenditure at 90.0% of revenue. Every figure is computed directly from PLSE's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $0M | -21982.6% | -20794.6% |
| FY2024 | $0M | n/a | n/a |
| FY2023 | $0M | n/a | n/a |
| FY2022 | $1M | -8293.9% | -8357.9% |
| FY2021 | $1M | -4443.9% | -4489.4% |
How does PLSE compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.